← Back to patent-cliff list
SHR-2150
Tier C — Watch / tradeSHR-2150
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TLR7
Indications (approved)：Solid tumour, HIV infection
Regional status
US
-
EU
-
China
Phase II
2020-10-10
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of SHR-2150?
Approved indications include: Solid tumour, HIV infection.
When does the SHR-2150 patent expire?
No public expiry year is available for SHR-2150 yet; this page updates once verified.
How do I get a quote for SHR-2150 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06